IMV Inc. (IMVIF) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
IMV Inc. (IMVIF) trades at $0.002 with AI Score 42/100 (Grade C). IMV Inc. is a clinical-stage biopharmaceutical company specializing in immuno-oncology therapies. Sector: Healthcare.
Price as of Jul 20, 2026 · Last analyzed: Jun 14, 2026Analyst Coverage for IMVIF: IMVIF does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates IMVIF against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
IMVIF: 1/3 scored disciplines lean bearish. Dominant signal: Ray Dalio bullish.
How is this calculated? →Why this analysis is different
- A 9-signal quantitative MoonshotScore built from filings, insider activity, and market data — computed from the numbers, not from opinion.
- An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
- Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.
IMV Inc. (IMVIF) Healthcare & Pipeline Overview
IMV Inc. (IMVIF) is a clinical-stage biopharmaceutical company focused on developing innovative immunotherapies for cancer and infectious diseases, leveraging its proprietary DPX platform to create targeted treatments for solid tumors and blood cancers.
What Is the Investment Thesis for IMVIF?
IMV Inc. presents a compelling investment thesis based on its innovative DPX platform and robust clinical pipeline. The company is advancing its lead candidate, maveropepimut-S, through critical Phase II trials, which could unlock significant market opportunities in the oncology space, particularly if successful in treating diffuse large B-cell lymphoma and ovarian cancer. The global immuno-oncology market is projected to grow substantially, with estimates reaching $110 billion by 2025, driven by increasing cancer incidence and advancements in treatment modalities. Additionally, IMV's development of immunotherapies for infectious diseases like COVID-19 and RSV adds diversification to its portfolio. However, potential risks include the inherent uncertainties of clinical trial outcomes and the challenges of securing funding in a competitive landscape. The company's ability to navigate these challenges while advancing its clinical programs will be key to unlocking shareholder value.
Based on FMP financials and quantitative analysis
IMVIF Key Highlights
- Market Cap: $0.00B, indicating a focus on clinical development with no current revenue.
- Beta: 0.30, suggesting lower volatility compared to the market.
- Employee count: 63, reflecting a lean operational structure.
- No dividend yield, emphasizing reinvestment in clinical trials and research.
- Focus on immuno-oncology, a rapidly growing sector within biotechnology.
Who Are IMVIF's Competitors?
IMVIF is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| BMY Bristol-Myers Squibb Company | $60.16 | -0.95% | $123B | 90 |
| NVS Novartis AG | $155.31 | +3.84% | $296B | 57 |
| JAZZ Jazz Pharmaceuticals plc | $243.47 | -1.64% | $15.3B | 58 |
| ADAPY Adaptimmune Therapeutics plc | $0.04 | -3.80% | $10.1M | 72 |
| JNCE Jounce Therapeutics, Inc. | $1.88 | +0.00% | $99.0M | 71 |
| ORMP Oramed Pharmaceuticals Inc. | $4.10 | +1.74% | $168M | 76 |
| CGEN Compugen Ltd. | $2.34 | -1.27% | $221M | 76 |
| NAGE Niagen Bioscience Inc | $3.37 | +2.74% | $268M | 69 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are IMVIF's Key Strengths?
- Innovative DPX platform enabling targeted immunotherapy development.
- Strong pipeline with multiple candidates in clinical trials.
- Experienced management team with expertise in biotechnology.
- Established presence in the immuno-oncology sector.
What Are IMVIF's Weaknesses?
- Currently no revenue, relying on funding for operations.
- Clinical-stage status involves significant risks and uncertainties.
- Limited market presence compared to larger competitors.
- Potential challenges in securing additional funding.
What Could Drive IMVIF Stock Higher?
- Results from Phase II clinical trials for maveropepimut-S expected in 2026.
- Development of DPX-SurMAGE in Phase I trials for bladder cancer.
- Initiation of Phase I trials for DPX-COVID-19 and DPX-RSV.
- Strategic partnerships to enhance research and development efforts.
- Potential announcements regarding funding or collaborations in 2026.
What Are the Key Risks for IMVIF?
- Financial-distress signal — its Altman Z-Score of -11.97 sits in the distress zone (elevated bankruptcy risk).
- Weak fundamentals — a Piotroski F-Score of 1/9 flags soft profitability, leverage or efficiency.
- Clinical trial outcomes remain uncertain and can impact stock performance.
- Regulatory challenges could delay product development timelines.
- Competition from established pharmaceutical companies in immuno-oncology.
- Market volatility affecting investor sentiment and funding availability.
What Are the Growth Opportunities for IMVIF?
- Expansion into Solid Tumor Markets: IMV Inc. is advancing maveropepimut-S through Phase II trials for various solid tumors, including ovarian cancer and bladder cancer. The solid tumor market is expected to grow significantly, with a projected CAGR of 8.5% through 2028, driven by increasing cancer incidence and a shift towards personalized medicine. Successful trial outcomes could position IMV to capture a share of this lucrative market.
- Development of DPX-SurMAGE: The ongoing Phase I evaluation of DPX-SurMAGE for bladder cancer represents a significant growth opportunity. The bladder cancer market is projected to reach $4.5 billion by 2025. If clinical trials demonstrate efficacy, IMV could establish itself as a key player in this therapeutic area, addressing unmet medical needs.
- Immunotherapy for Infectious Diseases: With the development of DPX-COVID-19 and DPX-RSV, IMV Inc. is tapping into the growing market for infectious disease therapies. The global market for infectious disease therapeutics is expected to reach $60 billion by 2027. This diversification not only mitigates risks associated with oncology but also positions IMV to benefit from increased demand for vaccines and therapies.
- Collaboration and Partnerships: IMV Inc. could explore strategic partnerships with larger pharmaceutical companies to enhance its research capabilities and expedite clinical trials. Collaborations can provide access to additional resources, funding, and expertise, potentially accelerating the development timeline for its therapies.
- Geographic Expansion: As IMV Inc. progresses through clinical trials, there may be opportunities to expand its market presence beyond North America into Europe and Asia. The global oncology market is expanding, and entering new regions could significantly increase the addressable market for IMV's therapies.
What Opportunities Does IMVIF Have?
- Growing demand for effective immunotherapies in oncology.
- Expansion into new therapeutic areas and geographic markets.
- Potential strategic partnerships to enhance development capabilities.
- Increasing interest in immunotherapy for infectious diseases.
What Threats Does IMVIF Face?
- Intense competition from established pharmaceutical companies.
- Regulatory hurdles and uncertainties in clinical trial outcomes.
- Market volatility impacting funding and investor sentiment.
- Rapid technological advancements in biotechnology.
What Are IMVIF's Competitive Advantages?
- Proprietary DPX immune-modulating platform that enhances immune responses.
- Focused expertise in immuno-oncology, differentiating it from competitors.
- Innovative drug delivery technology that targets specific cancer cells.
- Strong pipeline of clinical candidates addressing unmet medical needs.
- Established reputation in the biotechnology community since 2000.
What Does IMVIF Do?
Founded in 2000, IMV Inc., originally known as Immunovaccine Inc., is a biopharmaceutical firm headquartered in Dartmouth, Canada. The company is dedicated to advancing immuno-oncology therapies through its proprietary DPX immune-modulating platform, which enables the development of a range of treatments targeting both solid tumors and hematological malignancies. IMV's flagship product, maveropepimut-S, is an immunotherapy designed to target cells expressing survivin, currently undergoing Phase II clinical trials for diffuse large B-cell lymphoma, ovarian cancer, and various solid tumors, including those of the bladder and liver. Additionally, the company is investigating maveropepimut-S in Phase I trials for breast cancer. IMV's pipeline also includes DPX-SurMAGE, currently in Phase I evaluation for bladder cancer, as well as DPX-COVID-19 and DPX-RSV, which are aimed at addressing infectious diseases. The company has made significant strides since its inception, focusing on developing innovative therapies that leverage its unique drug delivery technology, which is designed to enhance immune responses against cancer cells. With a workforce of 63 employees, IMV Inc. is positioned to capitalize on the growing demand for advanced immunotherapies in the healthcare sector.
What Products and Services Does IMVIF Offer?
- Develop immunotherapies targeting cancer and infectious diseases.
- Utilize the proprietary DPX immune-modulating platform for drug delivery.
- Conduct clinical trials to evaluate the safety and efficacy of its therapies.
- Focus on solid tumors and blood cancers in its treatment pipeline.
- Engage in research collaborations to enhance therapeutic development.
- Seek regulatory approvals for its clinical-stage products.
How Does IMVIF Make Money?
- Generate revenue through the development and commercialization of innovative therapies.
- Engage in partnerships and collaborations with larger pharmaceutical companies.
- Leverage funding from grants and investors to support clinical trials and research.
- Potential future revenue from licensing agreements for its proprietary technologies.
- Focus on advancing clinical candidates to market for revenue generation.
What Industry Does IMVIF Operate In?
The biotechnology industry, particularly the immuno-oncology sector, is experiencing significant growth, driven by advancements in cancer therapies and increasing demand for personalized medicine. The global immuno-oncology market is projected to reach approximately $110 billion by 2025, fueled by rising cancer prevalence and the need for effective treatment options. IMV Inc. operates in a competitive landscape that includes established players and emerging biotech firms, positioning itself with its proprietary DPX platform, which differentiates its product offerings through targeted immune modulation. As clinical results emerge, companies like IMV that focus on innovative therapies are likely to capture market share and attract investor interest.
Who Are IMVIF's Key Customers?
- Healthcare providers and hospitals seeking advanced cancer treatments.
- Patients diagnosed with solid tumors and blood cancers.
- Pharmaceutical companies interested in collaboration and licensing.
- Research institutions conducting studies in immuno-oncology.
- Investors and stakeholders in the biotechnology sector.
FY2026 estForward Outlook
Wall Street analysts project IMV Inc. revenue of about $21.4M for fiscal 2026, with EPS near $-2.63.
F-Score 1/9Financial Health
IMV Inc.'s Piotroski F-Score is 1/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -11.97 places it in the distress zone, a signal of elevated financial risk.
IMV Inc. (IMVIF) Valuation Context
Relative to its peer group, IMVIF's quantitative score of 42/100 is below the peer average of 70/100.
IMVIF Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
Bull Case vs Bear Case
Bull Case
- Innovative DPX platform enabling targeted immunotherapy development.
- Strong pipeline with multiple candidates in clinical trials.
- Experienced management team with expertise in biotechnology.
- Established presence in the immuno-oncology sector.
Bear Case
- Currently no revenue, relying on funding for operations.
- Clinical-stage status involves significant risks and uncertainties.
- Limited market presence compared to larger competitors.
- Potential challenges in securing additional funding.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · July 2026
IMVIF Latest News
No recent news available for IMVIF.
IMVIF Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for IMVIF.
Price Targets
Wall Street price target analysis for IMVIF.
IMVIF MoonshotScore
What does this score mean?
The MoonshotScore rates IMVIF 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
Leadership: Andrew Hall
CEO
Andrew Hall has extensive experience in the biopharmaceutical industry, having held various leadership roles in both public and private companies. He has a strong background in drug development and commercialization, with a focus on oncology and immunotherapy. Hall holds an MBA and has been instrumental in guiding IMV Inc. through its clinical development phases.
Track Record: Under Andrew Hall's leadership, IMV Inc. has advanced its clinical pipeline significantly, particularly with the progress of maveropepimut-S through multiple phases of clinical trials. His strategic vision has positioned the company to explore new therapeutic areas and expand its market reach.
IMVIF OTC Market Information
OTC Other tier stocks, like IMV Inc., are subject to less stringent reporting requirements compared to those listed on major exchanges like NYSE or NASDAQ. This can lead to lower liquidity and potentially higher volatility, as these companies may not be required to file regular financial reports or maintain the same level of transparency.
- OTC Tier: OTC Other
- Lower liquidity compared to stocks listed on major exchanges.
- Less stringent reporting and transparency requirements.
- Potential for higher volatility due to market dynamics.
- Increased risk of price manipulation in less regulated markets.
- Review recent clinical trial results and their implications.
- Assess the company's financial health and funding status.
- Evaluate the competitive landscape and market positioning.
- Monitor regulatory developments affecting the biotechnology sector.
- Investigate potential partnerships or collaborations.
- Established presence in the biotechnology sector since 2000.
- Ongoing clinical trials with potential for significant market impact.
- Experienced management team with a track record in drug development.
What Investors Ask About IMV Inc. (IMVIF) — Healthcare
What does the AI Score mean for IMVIF?
IMVIF holds an AI Score of 42/100 (Grade: C). This is an educational research signal, not a buy or sell recommendation. IMV Inc. is a clinical-stage biopharmaceutical company specializing in immuno-oncology therapies. Utilizing its proprietary DPX immune-modulating platform, the company is advancing multiple …
What does IMV Inc. do?
IMV Inc. is a clinical-stage biopharmaceutical company focused on developing immunotherapies for cancer and infectious diseases. Utilizing its proprietary DPX immune-modulating platform, the company aims to create targeted treatments for solid tumors and blood cancers, advancing multiple candidates through clinical trials.
What are the key growth opportunities for IMVIF in healthcare?
IMV Inc. has several growth opportunities, including the advancement of maveropepimut-S through Phase II trials for various cancers, the development of DPX-SurMAGE for bladder cancer, and the exploration of immunotherapy for infectious diseases like COVID-19 and RSV. Additionally, potential partnerships and geographic expansion could further enhance growth prospects.
What are the main risks for IMVIF?
The primary risks for IMV Inc. include uncertainties surrounding clinical trial outcomes, which could significantly affect the company's future. Regulatory challenges may also pose delays in product development. Furthermore, competition from larger pharmaceutical firms in the immuno-oncology sector and market volatility could impact funding and investor sentiment.
What are the key factors to evaluate for IMVIF?
IMV Inc. (IMVIF) holds an AI score of 42/100 (low). Not financial advice.
How frequently does IMVIF data refresh on this page?
IMVIF's price was last updated on Jul 20, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven IMVIF's recent stock price performance?
IMV Inc. (IMVIF) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Innovative DPX platform enabling targeted immunotherapy development. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider IMVIF overvalued or undervalued right now?
IMV Inc. (IMVIF) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research IMVIF before investing?
Before investing in IMV Inc. (IMVIF), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Financial information may be limited due to OTC classification.